A new protocol for Treg expansion uses targeted immunotherapy to reduce transplant complications, boosting survival rates while preserving anti-cancer immunity. The protocol, led by Robert Levy, uses TL1A-Ig fusion protein and low-dose IL-2 to stimulate specific receptors on Tregs, promoting a safer environment for stem cell transplants.
A new study using magnetoelectric nanoparticles successfully shrinks pancreatic tumors in preclinical models, extending survival. The Sylvester Cancer Institute has also launched its Survivorship and Supportive Care Institute to provide evidence-based care for cancer patients.
Researchers from the University of Miami Miller School of Medicine and Sylvester Comprehensive Cancer Center will present their work on various hematological conditions at ASH 2025. These posters highlight recent findings in fields such as von Willebrand disease, multiple myeloma, and acute myeloid leukemia.
Multiple Sylvester physicians presented their research on various hematological cancers, including lymphoma and myeloma. The studies showcased promising results for treatments such as CAR-T therapy and immunotherapy combinations.
Researchers at University of Miami Miller School of Medicine have developed a new combination therapy that shrinks tumors, reduces cancer stem cells and reprograms immune environment to combat hormone-resistant breast cancer. The triple therapy approach targets tumor-associated macrophages, which act like bodyguards for cancer cells.
A new study found that magnetoelectric nanoparticles can locate and destroy pancreatic tumors in preclinical models, reducing tumor size by one-third and extending survival time. The treatment uses no drugs or invasive procedures, instead guiding the nanoparticles to the tumor site using a small magnet and activating them with an MRI s...
A phase 1 trial has investigated the combination of a ribonucleotide reductase inhibitor with lutetium Lu 177 dotatate, showing potential for improved treatment outcomes in patients with progressive GEP-NETs. The results have led to a planned phase 2 randomized trial to assess progression-free survival.
Recent studies from Sylvester have uncovered links between breast cancer, Superfund sites and social adversity. Researchers are also exploring the use of artificial intelligence (AI) in interpreting mammograms more accurately.
Mikkael Sekeres has been elected to the Executive Committee of the American Society of Hematology (ASH), a four-year term starting after the 2025 ASH Annual Meeting. He will help strengthen the organization's mission in shaping the future of hematology.
Women living close to Superfund sites in Florida face higher risks of developing aggressive breast cancers, including triple-negative subtype. A growing body of evidence suggests that environmental degradation and pollution are associated with poor health outcomes.
Researchers at Sylvester Comprehensive Cancer Center are pioneering innovative approaches to treating complex movement disorders with advanced imaging and radiosurgery techniques. The new era of functional radiosurgery enables precise treatment without invasive procedures.
Researchers from University of Miami Miller School of Medicine will showcase their study results at the annual conference. The presentation focuses on advancements in cancer treatment and patient care.
The PRISM trial will examine the impact of AI on mammogram accuracy and patient experience, with hundreds of thousands of mammograms analyzed. The study aims to understand whether AI enhances cancer detection by radiologists or leads to more false alarms.
Researchers found that glioblastoma cells in clusters are less deadly than those that disperse from these clusters. The dispersed cells are more plastic and resistant to therapy, making them a major contributor to treatment resistance and poor patient outcomes.
A new study shows that remote perioperative monitoring significantly improves recovery for cancer surgery patients, with a 6% greater functional recovery rate by day 14 after surgery. The study also found fewer major complications and improved symptom management.
A new study assesses ChatGPT 3.5's performance on hematology-oncology tasks, revealing its strengths and limitations in providing accurate information for patients. The study highlights the importance of physician oversight when using AI-generated medical information.
A new study reveals that DNA damage in multiple myeloma initiates 2-4 decades before diagnosis, with key genomic events including IGH translocation and chr 1q gain. These findings may lead to new precision medicine treatment strategies for patients.
A new model suggests that inhibiting the cellular molecule CREB might relieve damage to the pancreas and thwart tumor development in response to alcohol. The study found that knocking out CREB relieved precancerous and cancerous lesions, even with continued alcohol exposure.
The study uses Rapid Precision Run-On Sequencing (rPRO-seq) to uncover molecular drivers of cellular differentiation, offering a paradigm shift in understanding regenerative therapies. The technique allows doctors to analyze patients' disease states and treatment response in real-time.
Researchers found olutasidenib to be highly effective in patients with myelodysplastic syndrome (MDS) and IDH1 mutations. The study showed a response rate of 59% and improved blood count improvement, long duration of response, and overall survival rates. This breakthrough offers new treatment options for these patients.
A new study has found that TAF1 operates as a key molecular switch in adult hematopoietic stem cell maintenance and lineage commitment. This discovery challenges prevailing models of gene regulation and has the potential to lead to new therapeutic strategies targeting the molecule, which could improve blood production and transplantation.
A study documents elite-level strength training during active breast cancer treatment, showing rare retention of squat strength despite chemotherapy. LaShae Rolle, a competitive powerlifter and breast cancer survivor, completed the first-of-its-kind study, demonstrating the feasibility of high-intensity training when carefully managed.
New research from Sylvester Comprehensive Cancer Center shows that partial match transplants can achieve good outcomes with cyclophosphamide treatment. Additionally, lifestyle medicine is playing a pivotal role in improving patient outcomes for cancer survivors.
A recent study found that blood cancer patients achieve good outcomes with a partial match drawn from the national public registry of donors when treated with cyclophosphamide. Survival rates at one year were comparable to those seen in other studies with fully matched donors.
Sylvester researchers found that alcohol-related cancer deaths increased by nearly double from 1990 to 2021, primarily affecting men over 55. A new four-drug combination has been shown to be highly effective and safe in treating patients with newly diagnosed multiple myeloma.
Researchers found that combining selinexor with Irinotecan shrunk tumors in preclinical models of colorectal cancer, suggesting a new potential treatment. The study also identified XPO1 mutations linked to rare cancers like endometrial cancer and found that these mutations make cells resistant to chemotherapy.
A new study analyzed trends over time in alcohol-linked cancer mortality across the US, finding nearly double the number of alcohol-related cancer deaths between 1990 and 2021. The burden is highest among men over 55, with liver, colorectal, and esophageal cancers seeing significant increases.
A new four-drug combination, DKRd, has emerged as a highly effective and safe treatment for newly diagnosed multiple myeloma patients. The ADVANCE clinical trial shows that 59% of patients treated with DKRd were MRD-negative after eight cycles of treatment, compared to 36% of KRd-treated patients.
Researchers from Sylvester will present on various cancer-related topics, including multiple myeloma, hematopoietic stem cell transplantation, and melanoma. The presentations focus on innovative treatments and supportive care interventions.
Multiple myeloma research saw breakthroughs with carfilzomib and daratumumab combinations. Hematopoietic stem cell transplant patients benefited from a virtual reality supportive care intervention. New treatments for chemotherapy-induced thrombocytopenia were also explored, including romiplostim.
Researchers are exploring the use of immunotherapy drugs and a tumor-busting 'oncolytic' virus to tackle high-grade neuroendocrine tumors. A new clinical trial, led by Dr. Aman Chauhan, aims to unlock the mysteries of renal cell carcinoma through detailed laboratory and clinical studies.
A new clinical trial at the University of Miami Miller School of Medicine is testing a novel combination of immunotherapy drugs and an oncolytic virus to treat high-grade neuroendocrine cancer. The trial aims to find safe combination doses and compare effectiveness with standard-of-care treatment.
New leukemia treatment combination shows promise for patients with follicular lymphoma. Immunotherapy research also explores ways to suppress protein ZNF638 to boost effectiveness of immune checkpoint inhibitors. Innovative funding efforts support Sylvester's cancer research initiatives.
The updated guidelines substantially increased lung cancer screenings overall, but disparities persist among people with limited access to healthcare. Barriers include cost, knowledge, and lack of primary care providers, with mobile units and patient navigators offering potential solutions.
Researchers found that suppressing ZNF638 triggers an antiviral immune response in glioblastoma patients, making them more susceptible to treatment. This finding offers a potential new treatment strategy for the disease, which has remained challenging despite recent advances in immunotherapy.
Sylvester's Firefighter Cancer Initiative reduces cancer risk among firefighters and community members by addressing electric vehicle fires. A new gene-editing study aims to treat mitochondrial diseases, while a program connects patients with pathologists to improve understanding of complex results.
The FDA has revoked authorization for the use of Red Dye 3 in food and ingested drugs, citing studies linking it to cancer in laboratory male rats. This decision is an important step forward in addressing modifiable risk factors that have the potential to reduce cancer risk.
A new study found that while lung cancer deaths decreased globally from 1990 to 2019, mortality linked to tobacco use and air pollution increased. Tobacco remains the leading cause of death, accounting for 66% of TBL cancer deaths in 2019, while particulate matter pollution is a growing concern.
Preliminary research suggests that grieving a public figure's death can be similar to grieving a personal relationship, with intense emotions and lasting impact. Dr. Wendy Lichtenthal's work focuses on advancing bereavement science and 'meaning-centered' grief therapy for families and caregivers.
Sylvester Comprehensive Cancer Center offers expert advice on coping with holiday loss and grief. Biological age can predict early colorectal cancer risk, while research advances may lead to a cure for multiple myeloma. Blood cancer experts share insights into new treatments.
Stephen D. Nimer, MD, has been awarded the American Society of Hematology's (ASH) Mentor Award for 2024 for his impact on over 100 hematology trainees who have gone on to have thriving careers. He is recognized for creating a collaborative environment that drives scientific discovery and quality patient care.
A new review published in Blood Cancer Discovery outlines how research supported a recent FDA committee decision to allow minimal residual disease as an endpoint for accelerated approval in multiple myeloma. This decision could cut a decade off the drug development process, enabling faster innovation in cancer treatment.
A new study suggests that a person's biological age can predict their risk of developing colon polyps and early colorectal cancer. Accelerated aging, which is higher than chronological age, may be linked to a greater risk of developing the disease, highlighting the importance of early screening.
Researchers are working to develop a curative treatment for multiple myeloma by combining treatments, overcoming resistance, and tailoring therapy to individual patients. The study found promising results using bispecific antibodies in combination with other treatments.
The study found that smokers with myelodysplastic syndromes (MDS) or precursor conditions had elevated levels of genetic mutations linked to the disease. Heavier smokers accumulated more mutations, and long-term smokers were more likely to show disease progression.
Two clinical trials testing loncastuximab tesirine showed promising results in patients with high-risk forms of follicular lymphoma and marginal zone lymphoma. The treatment achieved impressive response rates, including a 70% complete response rate for marginal zone lymphoma and an overall response rate of 97% for follicular lymphoma.
Sylvester researchers will present over 130 studies at ASH 2024, addressing disparities in gastric cancer. Frank J. Penedo's research highlights worse outcomes for patients with unmet supportive needs, while Shria Kumar's work seeks answers for disparities in gastric cancer among specific minorities.
More than 70 hematology researchers from the University of Miami Miller School of Medicine will showcase their work at the 66th ASH Annual Meeting & Exposition. Researchers from Sylvester Comprehensive Cancer Center are authors or co-authors on a significant number of posters presented during the event.
Researchers from the Sylvester Comprehensive Cancer Center presented their findings on the association between smoking intensity, genetic mutations, and disease progression in myelodysplastic syndromes. Dr. Stephen D. Nimer received the 2024 ASH Mentor Award for his impact on hematology trainees.
A new study from Sylvester Cancer suggests that changes in reproductive health, including earlier menarche and lower birth rates, may contribute to the higher breast cancer risk among Caribbean women. The findings highlight the importance of public health interventions targeting modifiable risk factors such as diet and exercise.